NYXH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.47M

+175.02%

-0.538

+16.11%

4.61M

+333.14%

-0.535

-10.49%

6.45M

+381.48%

-0.546

-0.82%

Estimates Revision

The market is revising Downward the revenue expectations for Nyxoah SA (NYXH) for FY2025, with the revenue forecasts being adjusted by -6.56% over the past three months. During the same period, the stock price has changed by -20.06%.

Revenue Estimates for FY2025

Revise Downward

-6.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-24.26%

In Past 3 Month

Stock Price

Go Down

-20.06%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is 11.54 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

11.54

High

13.00

Current: 0.000

Low

9.00

Averages

11.54

High

13.00

Baird

Neutral

downgrade

2025-12-16

Reason

Baird

Price Target

2025-12-16

downgrade

Neutral

Reason

Baird lowered the firm's price target on Nyxoah to EUR 5 from EUR 7 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.

Piper Sandler

Overweight

downgrade

$12 -> $9

2025-11-14

Reason

Piper Sandler

Price Target

$12 -> $9

2025-11-14

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Nyxoah to $9 from $12 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 revenue of EUR 2.0M, which came in-line with its estimate and the Street's bogey. The U.S. Genio launch appears to be progressing nicely, with Nyxoah announcing that it has done 15 U.S. implants and received 35 VAC approvals through the end of October. Piper understands the process to receive VAC and prior authorization approvals can be onerous and believes that the Q4 guidance of EUR 3.4M - EUR 3.6M feels appropriately calibrated.

Stifel

Jonathan Block

Strong Buy

Maintains

$15 → $14

2025-04-21

Reason

Stifel

Jonathan Block

Price Target

$15 → $14

2025-04-21

Maintains

Strong Buy

Reason

Stifel analyst Jonathan Block lowered the firm's price target on Nyxoah (NYXH) to $14 from $15 and keeps a Buy rating on the shares. The firm lowered its FY25-FY28 estimates but largely maintains its FY29 U.S. Genio market share estimate of about 16%, which assumes a U.S. duopoly with Inspire Medical (INSP). The firm expects Nyxoah's label to be favorable to Inspire's and prior diligence suggested 50%-plus of non-academic centers want to get trained on Genio within about six months of commercialization, which it calls "a greater uptake than Inspire's high-level comments suggest."

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

$15

2025-04-08

Reason

HC Wainwright & Co.

Edward White

Price Target

$15

2025-04-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Maintains

$17 → $15

2025-03-26

Reason

HC Wainwright & Co.

Edward White

Price Target

$17 → $15

2025-03-26

Maintains

Strong Buy

Reason

Stifel

Jonathan Block

Strong Buy

Maintains

$16 → $15

2025-03-14

Reason

Stifel

Jonathan Block

Price Target

$16 → $15

2025-03-14

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on Nyxoah to $15 from $16 and keeps a Buy rating on the shares. For the quarter, revenue was "light," offset by better-than-expected gross margin, but "it is all about U.S. Genio approval and the subsequent ramp," the analyst tells investors in an earnings recap note.

Valuation Metrics

The current forward P/E ratio for Nyxoah SA (NYXH.O) is -1.80, compared to its 5-year average forward P/E of -6.15. For a more detailed relative valuation and DCF analysis to assess Nyxoah SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.15

Current PE

-1.80

Overvalued PE

-0.72

Undervalued PE

-11.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.49

Current EV/EBITDA

-1.69

Overvalued EV/EBITDA

-0.40

Undervalued EV/EBITDA

-10.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

45.51

Current PS

7.36

Overvalued PS

101.64

Undervalued PS

-10.61

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NYXH News & Events

Events Timeline

No data

News

1.0

2025-12-29Globenewswire

Nyxoah to Present Innovative OSA Treatment at 44th J.P. Morgan Healthcare Conference

8.5

2025-12-19Globenewswire

Nyxoah Issues €22.5 Million First Tranche of Convertible Bonds

8.5

2025-12-19Newsfilter

Nyxoah Issues €22.5 Million First Tranche of Convertible Bonds

People Also Watch

Frequently Asked Questions

What is Nyxoah SA (NYXH) stock price today?

The current price of NYXH is 5.1 USD — it has increased 1.8 % in the last trading day.

What is Nyxoah SA (NYXH)'s business?

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

What is the price predicton of NYXH Stock?

What is Nyxoah SA (NYXH)'s revenue for the last quarter?

Nyxoah SA revenue for the last quarter amounts to 1.97M USD, increased 55.77 % YoY.

What is Nyxoah SA (NYXH)'s earnings per share (EPS) for the last quarter?

Nyxoah SA. EPS for the last quarter amounts to -0.63 USD, increased 26.00 % YoY.

What changes have occurred in the market's expectations for Nyxoah SA (NYXH)'s fundamentals?

How many employees does Nyxoah SA (NYXH). have?

Nyxoah SA (NYXH) has 147 emplpoyees as of January 10 2026.

What is Nyxoah SA (NYXH) market cap?

Today NYXH has the market capitalization of 219.43M USD.